Drugs & Targets

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. 
Clinical Roundup

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

Findings from two subset analyses of the phase III MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer demonstrate an overall survival and progression-free survival benefit. 
Clinical RoundupFree

Researchers identify biological signature that may identify refractory ovarian cancer patients

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, and University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.
Clinical Roundup

Elahere demonstrates OS benefit in the phase III MIRASOL trial in FRα-positive, platinum-resistant ovarian cancer

The phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55), which evaluated the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer who have received one to three prior lines of therapy, demonstrated statistically significant improvements in progression free survival, overall response rate, and overall survival compared to chemotherapy.